Impact of lung cancer screening in patients diagnosed with small cell lung cancer.

8102 Background: The advent of immunotherapy significantly improved overall survival (OS) for limited-stage SCLC (LS-SCLC), highlighting how early detection may drive maximal therapeutic benefit. Lung cancer screening (LCS) with low-dose CT scans (LDCT) in high-risk individuals reduced the risk of lung cancer mortality and identified more Stage I lung cancer (National Lung Screening Trial (NLST), NELSON). Within the NLST, SCLC distribution by stage (I-IV) was similar between LDCT or chest x-ray, thereby limiting the perceived absolute impact of LCS for SCLC detection. Here, we report on the utility of LCS in SCLC in the era of immunotherapy. Methods: We retrospectively reviewed the charts of patients diagnosed with SCLC in the Indiana University (IU) Health System from 2018 to 2024. Patients were stratified by whether SCLC was identified from LDCT or non-screen detected. Kaplan-Meier, Wilcoxon rank sum, Pearson’s Chi-squared, and Fisher’s exact test were applied. Results: Among the 301 LCS-eligible individuals with SCLC, 67 patients (22.3%) received LDCT preceding their diagnosis. With LDCT, a significant shift in stage was observed ( P 0.9 ECOG PS (0-1) 150 (70%) 53 (84%) 203 (73%) 0.024 Current tobacco 171 (73%) 50 (75%) 221 (73%) 0.9 COPD 119 (51%) 48 (72%) 167 (55%) 0.003 +FH cancer 128 (59%) 46 (73%) 174 (62%) 0.047 +FH lung cancer 57 (26%) 22 (35%) 79 (28%) 0.2